Vericel Corp stock is traded at $51.78, with a volume of 2,680,092. It is up +13.85% in the last 24 hours and up +26.08% over the past month. Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Previous Close:
$45.48
Open:
$50.54
24h Volume:
2,680,092
Relative Volume:
2.88
Market Cap:
$2.65B
Revenue:
$292.09M
Net Income/Loss:
$21.46M
P/E Ratio:
126.57
EPS:
$0.4091
Net Cash Flow:
$47.49M
1W Performance:
+20.67%
1M Performance:
+26.08%
6M Performance:
+40.67%
1Y Performance:
+39.19%
1-Day Range:
$49.00$55.60
1-Week Range:
$39.44$55.60
52-Week Range:
$28.95$55.60
Vericel Corp Stock (VCEL) Company Profile
Name
Vericel CorpSector
HealthcareIndustry
BiotechnologyPhone
(734) 930-5555Address
64 SIDNEY ST., CAMBRIDGE, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS